Phase 3Data readout

VYD2311

COVID-19

IVVDINVIVYD

Expected catalystSeptember 30, 2026Company guidance: Sep 30, 2026

Catalyst overview

Event details

Drug or asset: VYD2311
Development stage: Phase 3
Event type: Data readout
Indication: COVID-19

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 3 data readout for VYD2311 in COVID-19. The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- DECLARATION data shifted to Q3 2026. LIBERTY starts shortly. DRUMMER pediatric plan agreed. 06/01/26:- DECLARATION enrollment completed; topline results still expected in Late Q3 2026. 06/09/26:- First participants dosed in LIBERTY Ph3. LIBERTY topline data expected in Q3 2026. 06/16/26:- LIBERTY Ph3 enrollment completed; initial results expected in Q3 2026. 08/13/26:- DECLARATION enrollment completed and analysis is approaching. LIBERTY is fully dosed; both Ph3 topline datasets are expected in Late Q3 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source